▼ 0.92%
prev close
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2022-12-12 | NOTVInotiv, Inc. | Sell | $1,001 - $15,000 | 1168d ago | — |
2022-12-12
Christopher L. Jacobs
NOTV
Amount
$1,001 - $15,000
Filed
1168d ago
Recent News
Powered by Polygon.io
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
Trade Timeline
Congressional activity, newest first
Christopher L. Jacobs
2022-12-12 · Sale
$1,001 - $15,000